Cleland, Dargie, Ball, Gillen, Hodsman, Morton, East, Robertson, Ford, Robertson in the treatment of cardiac failure together with several substantial additional benefits. Angiotensin II is an important stimulus to aldosterone secretion7; and lowering plasma angiotensin II by angiotensin converting enzyme inhibition should reduce aldosterone secretion and thus facilitate diuresis while also correcting any deficiency of potassium and magnesium associated with diuretic therapy and aldosterone excess. 89 Hyperaldosteronism is particularly likely to occur with prolonged diuretic treatment of heart failure and the resulting electrolyte abnormalities predispose patients to cardiac arrhythmias.'011
The high circulating concentrations of angiotensin II encountered in heart failure can stimulate excessive secretion of vasopressin12 which hinders diuresis.i3 Reduction of vasopressint secretion by angiotensin converting enzyme inhibition should promote fluid excretion. Angiotensin II also stimulates the sympathetic nervous system at various sites14 and inhibits vagal transmission15; angiotensin converting enzyme inhibition will reverse these actions.16i7 Angiotensin II also has direct renal actions in cardiac failure. Despite a profound reduction in renal blood flow, i8 glomerular filtration rate and urea excretion 819 are well preserved until a late stage of heart failure. This maintenance of renal function is mainly the result of the intrarenal actions of angiotensin II which increases efferent glomerular arterial tone20 and enhances the efficiency of vasa recta countercurrent exchange mechanisms. 19 In late cardiac failure, however, excessive intrarenal angiotensin II can cause glomerular shutdown with rapidly advancing uraemia and hyponatraemia. 19 Thus angiotensin converting enzyme inhibition might benefit the kidney in advanced heart failure, but at earlier stages might worsen some aspects of renal function.
Several well controlled trials of angiotensin converting enzyme inhibition in cardiac failure have now shown clinical benefit,21 -25 although, to our knowledge, only one using captopril has concurrently evaluated symptoms together with metabolic, hormonal, and renal changes. 26 We report here the effects of enalapril, a new long acting angiotensin converting enzyme inhibitor, determined in 20 patients with heart failure in a trial with a double blind cross over design for within patient comparisons. In addition to assessing symptoms and exercise performance we measured renal function, serum and total body electrolytes, the renin-angiotensin system, and plasma aldosterone, vasopressin, and catecholamine concentration.
Patients and methods

PATIENT SELECTION
We studied 20 patients with chronic heart failure caused by ischaemic heart disease (nine), congestive (dilated) cardiomyopathy (eight), or severe left ventricular dysfunction after successful valve replacement (three) who were in New York Heart Associ- Weight increased in the first week on enalapril (0 4 (08) kg; p < 0 05) whereas there was no change after one week on placebo (-0 1(0-6) kg). One patient had weight gain with increased ankle swelling; the latter improved on continued therapy without alteration of diuretic dose. Weight was similar on placebo and enalapril at the end of both two month periods.
Adverse responses included hypokalaemia (serum potassium < 3-5 mmol/l) in eight patients on placebo; slight increases in transaminases, one patient on placebo (alanine transaminase 62 U/1) and one on enalapril (60 U/1); and a pronounced increase in serum urea (6) (7) (8) she made an uncomplicated recovery. One patient who had previously had raised fasting blood glucose (8 mmol/l at baseline) developed glycosuria and a further increase in his fasting blood glucose on enalapril (placebo 11 9 mmol/l, enalapril 13-4 mmol/l) which he had received after placebo.
Discussion
The present trial has confirmed earlier reports of beneficial effects on exercise time and dyspnoea in patients with heart failure treated with the angiotensin converting enzyme inhibitors captopril2l-26
and enalapril. The degree of improvement in exercise performance was similar to that observed in other studies of enalapril but the placebo response in our study was also much greater than that reported in other studies. 24 25 Our study design precludes any effect of patient training, allows within patient comparison of drug and placebo responses, and avoids difficulties in matching the baseline characteristics in placebo and active treatment groups which have affected other studies. 24 We saw no evidence of an order effect, indicating that the double blind treatment periods were long enough to exclude a carry over effect into placebo period, which would tend to cause drug action to be underestimated. Unlike the other two reported studies of enalapril regular diuretic therapy was unchanged in our patients. 2425 A single daily dose of enalapril was sufficient to sustain a reduction in angiotensin II and an increase in active renin over 24 hours. Mean plasma aldosterone, noradrenaline, and vasopressin concentrations were raised before angiotensin converting enzyme inhibition, and correlated significantly with angiotensin II concentration. When angiotensin II formation was inhibited concentrations of all of these hormones fell. This could have been the result of clinical improvement, but a reduction of the reported stimulatory effect of angiotensin II on sympathetic neuronal activity and on the secretion of vasopressin and aldosterone7 is more likely. A decrease in plasma noradrenaline has already been reported after both short'&40 and long term'626 angiotensin converting enzyme inhibition in patients
heart failure. We do not know of other reports of evidence of suppression of vasopressin secretion although such an effect is likely. Controlled studies of angiotensin converting enzyme inhibition in heart failure have consistently demonstrated long term suppression of plasma aldosterone26 41 42 perhaps caused by the counter regulatory effect of increased serum potassium concentration.43 A fall of plasma aldosterone could be important in maintaining sodium balance as blood pressure and glomerular filtration rate fall. Reduction in sympathetic activity and of plasma vasopressin concentrations may result in additional arterial and venous dilatation43 44; the latter is likely to promote excretion of water. 13 We found that serum potassium and magnesium concentrations rose on enalapril, and this effect may have been largely a result of a related fall in plasma aldosterone. In contrast to our earlier study with captopril,26 the rise in mean total body potassium on enalapril was not statistically significant. The increase of body potassium on enalapril was directly related to the baseline plasma renin. Moreover, the extent of initial potassium depletion is related to plasma renin. 45 Thus increases in total body potassium with angiotensin converting enzyme inhibition might be expected only in patients who are already potassium depleted. Transient weight gain, which we have also observed with captopril,26 occurred in the first week of enalapril therapy. This was probably largely due to a fall in blood pressure and possible renal dysfunction." In the long term weight was unchanged, suggesting that there may have been a secondary diuresis probably aided by the falls in plasma aldosterone and vasopressin. We observed no long term changes in mean serum sodium or total body sodium. There was a significant reduction in ventricular extrasystoles during enalapril treatment, probably partly reflecting the increases in serum potassium and magnesium, the reduction in sympathetic activity, and the reduced cardiac dimensions. Several studies have shown that frequent ventricular extrasystoles indicate a poor prognosis in heart failure,4748 and sudden death, presumably from arrhythmias, is common in patients with left ventricular failure.49 If a causal relation does exist this is one mechanism whereby angiotensin converting enzyme inhibitors might reduce mortality.
As we had expected on theoretical grounds20 and from earlier experience26 enalapril treatment, although it increased renal blood flow, led to a fall in both creatinine clearance and in glomerular filtration rate measured isotopically and an increase in serum urea and creatinine concentrations. These 52 53 hyponatraemia, and rapidly advancing azotaemia, are angiotensin converting inhibitors likely to improve renal function.
Reduction in heart rate is to be expected with angiotensin converting enzyme inhibition in cardiac failure despite dilatation of resistance vessels and probably results from a combination of venous dilatation, reduced sympathetic tone,'6 45 and loss of the vagolytic effect of angiotensin I1. 15 1 Although in the long term the reduction in blood pressure was generally well tolerated, initiation of treatment with captopril54 55 or enalapril56 may be associated with severe hypotension, bradycardia, and syncope. For this reason such treatment must be started under close supervision.
In response to the presumed reduction in preload and afterload57 58 we observed a reduction in left ventricular dimensions. An improvement in systolic function is suggested by the improvement in the ratio of pre-ejection period to left ventricular ejection time which has been shown to correlate with left ventricular fraction. 28 The reduction in end diastolic dimension implies a reduction in filling pressure.
Apart from postural hypotension which caused symptoms in three patients, adverse reactions seemed to be no more common with enalapril than with placebo. Although very low ambulant pressures without symptoms seem to be tolerated by many patients, an excessive fall below renal autoregulatory thresholds may have accounted for the pronounced increase in serum creatinine associated with hypotension and hyponatraemia in one patient. The patient who developed diabetes did so at the end of the four months of study and had had raised fasting blood glucose concentrations before joining the study. Impaired glucose metabolism does not seem to be a feature of angiotensin converting enzyme inhibition,59 however, in one study blood glucose concentration was not included in the coronary risk factors studied. 60 Despite the minor consequent impairment of renal function and occasional hypotension, angiotensin converting enzyme inhibitors clearly improve symptoms in heart failure. 
